Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[TYR34]bPTH-(7-34) is a synthetic peptide fragment of bovine parathyroid hormone (bPTH) spanning residues 7 to 34, with a tyrosine substitution at position 34. It functions as a specific and competitive antagonist of the Parathyroid Hormone Receptor 1 (PTHR1), blocking the signaling pathways typically activated by parathyroid hormone (PTH) and parathyroid hormone-related protein (PTHrP). In preclinical research, particularly in the study of multiple myeloma and bone metabolism, this peptide is used as a pharmacological tool to investigate the role of the PTH/PTHR1 axis in disease progression and therapeutic response. Research has demonstrated that [TYR34]bPTH-(7-34) can abrogate the bone-anabolic and anti-myeloma effects induced by proteasome inhibitors like bortezomib, indicating that the PTHR1 pathway is a critical mediator of the osteoblastic response in the myeloma bone marrow microenvironment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [TYR34]bPTH-(7-34).